Infinity Pharmaceuticals Announces Two Upcoming Presentations on PI3K-γ and Eganelisib by Dr. Judith Varner at the 2023 Annual Meeting of the American Association of Cancer Research
13 Abril 2023 - 3:05PM
Business Wire
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the
“Company”), a clinical-stage biotechnology company developing
eganelisib, a potential first-in-class, oral, immuno-oncology
macrophage reprogramming therapeutic, today announced upcoming
presentations including data on eganelisib by Infinity’s
collaborator, Professor Judith A. Varner of the UCSD Moores Cancer
Center, La Jolla, California, at the 2023 Annual Meeting of the
American Association of Cancer Research (AACR) to be held April 14
- 19, 2023 in Orlando, Florida.
Highlights of the presentations include preclinical and
translational data further reinforcing the mechanism of action of
PI3K-γ inhibition:
- Single cell transcriptomics data showing PI3K-γ knockout
switches tumor associated macrophages in head and neck squamous
cell carcinoma (HNSCC) and non small cell lung cancer (NSCLC) tumor
models to activated, antigen-presenting, T cell-stimulating
macrophages.
- Preclinical data supporting tumor growth delay of HNSCC tumor
models in PI3K-γ knockout mice is mediated by intra-tumoral
interleukin-12, interferon gamma and CD8+ T cells, key drivers of
immune response to cancer.
- Translational data from the MARIO-275 clinical trial showing
increased systemic immune activation in patients treated with
nivolumab in combination with eganelisib over nivolumab alone, with
enrichment of genes from interferon signaling, antigen
presentation, and T cell receptor pathways.
- Translational data from the MARIO-3 clinical trial, showing
immune activation within the tumor microenvironment in patients
treated with eganelisib, nab-paclitaxel and atezolizumab, with
up-regulation of interferon signaling, antigen presentation, and T
cell receptor pathways.
- Following translational data from MARIO-1 indicating increased
expression of the TGF-β activating integrin αVβ8 in HNSCC patients
treated with combination of eganelisib and nivolumab, initial
preclinical studies showing anti-αVβ8 monoclonal antibody treatment
prevents growth of HNSCC tumor model in PI3K-γ knock-out mice.
“Our presentations describe exciting aspects of the role of
PI3K-γ as a fundamental molecular switch controlling immune
response by myeloid cells in the tumor microenvironment,” said
Professor Varner. “Our preclinical data suggest key roles for
antigen-presenting activated macrophages, intra-tumoral IL-12,
IFN-γ release and activated CD8+ T cells in mediating the effect of
PI3K-γ knockout or PI3K-γ inhibition in tumor models. In line with
our preclinical studies, emerging translational data from the
MARIO-275 and MARIO-3 clinical trials support the mechanism of
action of eganelisib through reprogramming and activation of tumor
associated macrophages to reshape the tumor microenvironment and
favor anti-tumor activity. Altogether, these data continue to
underscore the potential of eganelisib as a next generation
macrophage reprogramming immunotherapeutic, in combination with
checkpoint inhibitors or potentially new immuno-oncology agents
like anti-αVβ8 monoclonal antibodies.”
Details of the presentations are as follows:
Presentation time: Saturday, April 15, 2023,
8:30am-8:50am EDT Title: Macrophages rule in cancer
Session: ED034 - Antigen Presentation: The
Macrophage-Dendritic Cell Debate Presenter: Judith A.
Varner
Presentation time: Tuesday, April 18, 2023,
10:20am-10:40am EDT Title: Basic and clinical impacts of
targeting myeloid cells in tumors Session: Session SY14 -
Next Generation of Myeloid Checkpoints in Cancer Presenter:
Judith A. Varner
About Infinity and Eganelisib
Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”), is
a clinical-stage biotechnology company developing eganelisib
(IPI-549), a potential first-in-class, oral, immuno-oncology
macrophage reprogramming therapeutic designed to address a
fundamental biologic mechanism of immune suppression in cancer.
MARIO-3 is a clinical study evaluating eganelisib in combination
with atezolizumab and nab-paclitaxel in front-line triple negative
breast cancer (TNBC) and in combination with atezolizumab and
bevacizumab in front-line renal cell carcinoma (RCC). MARIO-275 is
a randomized, controlled combination study of eganelisib combined
with nivolumab in I/O naïve urothelial cancer. For more information
on Infinity, please refer to Infinity's website at
www.infi.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. Such forward-looking statements include the therapeutic
potential of eganelisib including its potential as a
first-in-class, oral, immuno-oncology macrophage reprogramming
therapeutic. Such statements are subject to numerous important
factors, risks and uncertainties that may cause actual events or
results to differ materially from the Company's current
expectations. For example, there can be no guarantee that
eganelisib will successfully complete necessary preclinical and
clinical development phases. Further, there can be no guarantee
that any positive developments in Infinity's product portfolio will
result in stock price appreciation. Management's expectations and,
therefore, any forward-looking statements in this press release
could also be affected by risks and uncertainties relating to a
number of other factors, including the following: the cost, timing
and results of clinical trials and other development activities
that may be delayed or disrupted by the COVID-19 pandemic or
otherwise; the content and timing of decisions made by the U.S. FDA
and other regulatory authorities; Infinity's ability to obtain and
maintain requisite regulatory approvals; unplanned cash
requirements and expenditures; development of agents by Infinity's
competitors for diseases in which Infinity is currently developing
or intends to develop eganelisib; and Infinity's ability to obtain,
maintain and enforce patent and other intellectual property
protection for eganelisib. These and other risks which may impact
management's expectations are described in greater detail under the
caption "Risk Factors" included in Infinity's annual report and
quarterly reports filed with the Securities and Exchange Commission
(SEC), and in other filings that Infinity makes with the SEC,
available through the Company’s website at www.infi.com. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Infinity does not undertake and
expressly disclaims any obligation to update any forward-looking
statements, whether as a result of new information, future events
or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230413005147/en/
Melissa Hackel, melissa.hackel@infi.com
Infinity Pharmaceuticals (NASDAQ:INFI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Infinity Pharmaceuticals (NASDAQ:INFI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024